Twenty-nine women, ages 30-58 years, with advanced ovarian carcinoma w
ere treated with a developmental combination chemotherapy regimen cons
isting of mitomycin C, etoposide, cisplatin, and carboplatin (MECCA).
This protocol utilized the concepts of dose intensity, front-end loadi
ng, non-cross-resistance, and synergy. The median overall survival was
37 months with a 27% 5-year survival; the median failure-free surviva
l was 15 months with a 14% 5-year failure-free rate. The predominant t
oxicity was hematologic and there was one toxic death (cardiac failure
). The overall survival results are superior to our previous experienc
e. (C) 1996 Academic Press, Inc.